Roche says divarasib cut risk of death 44% in lung cancer trial

Impact · against what's priced in

Roche's positive Phase 3 data for divarasib provides a concrete catalyst for long-term EPS growth in the lung cancer market. The 44% reduction in death risk establishes a strong clinical profile likely to support regulatory approval and commercial adoption.

ROG+0.80: No priced-in read yet
In context: The reported 44% reduction in the risk of death for lung cancer patients using divarasib provides strong clinical evidence for a potential new revenue stream and regulatory filing.
Read from the article alone

Roche says divarasib cut risk of death 44% in lung cancer trial

clinical trials▲153%
biotech▲37%
pharmaceuticals
ROG
lung cancer
oncology
roche

Top 2 movers · tap to explore

Roche says divarasib cut risk of death 44% in lung cancer trial

What matters in this story

How each ticker is affected

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Roche says divarasib cut risk of death 44% in lung cancer trial

What matters in this story

How each ticker is affected

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Track these names every morning.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Roche says divarasib cut risk of death 44% in lung cancer trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Roche says divarasib cut risk of death 44% in lung cancer trial

What matters in this story

How each ticker is affected

Next reads from the same story arc

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Track these names every morning.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026